CVRX

Business Context and Reporting Period

CVRx, Inc. (CVRX) is a commercial-stage medical device company focused on the Barostim neuromodulation system for heart failure with reduced ejection fraction (HFrEF) and resistant hypertension. This Form 10-Q covers the quarterly period ended September 30, 2025. The company operates as a single reportable segment with revenue derived primarily from the U.S. and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q3 2025 revenue increased 10% year-over-year (YoY) to $14.69M, driven by a 10% increase in U.S. sales ($13.49M) and a 12% increase in European sales ($1.20M). U.S. revenue units rose to 420 from 394 in the prior year quarter.
• Margin Expansion: Gross margin improved to 87% in Q3 2025 from 83% in Q3 2024, attributed to higher average selling prices and manufacturing efficiencies reducing cost per unit.
• Expense Management: Total operating expenses increased slightly by 4% in Q3 ($25.02M vs. $24.14M). However, on a YTD basis, operating expenses decreased 6% to $74.60M, primarily due to an $8.0M reduction in non-cash stock-based compensation compared to the prior year (which included an $8.4M charge related to a former CEO's retirement in 2024).
• Loss Reduction: Net loss narrowed by 2% in Q3 and 16% on a YTD basis compared to the prior year periods.
• Commercial Footprint: Active implanting centers in the U.S. grew to 250 (from 208 in Q3 2024), and sales territories expanded to 50 (from 45).

Guidance, Outlook, and Risks

• Reimbursement Milestone: The Centers for Medicare & Medicaid Services (CMS) released the final 2026 Physician Fee Schedule establishing new Category I CPT codes for Barostim, effective January 1, 2026. Management expects this to eliminate automatic denials and improve prior authorization predictability.
• Liquidity and Capital Resources: As of September 30, 2025, the company held $85.1M in cash. Management believes existing resources are sufficient to meet operating and debt service requirements for at least the next two years, with principal debt payments commencing in November 2027.
• Financing Activities: The company terminated its At-The-Market (ATM) offering agreement on November 4, 2025, after raising $9.5M in the first nine months of 2025. A new registration statement is expected to be filed to permit future ATM activity.
• Debt Obligations: The company has $50.0M in outstanding term loans under an agreement with Innovatus Life Sciences. Interest-only payments are required through November 2027, followed by principal repayments starting in December 2027.
• Risk Factors: Key risks include continued operating losses, dependence on the single Barostim product, reimbursement challenges, supply chain dependencies, and the need to demonstrate long-term clinical data. The company also faces regulatory compliance requirements under the EU Medical Device Regulation (MDR), for which it received final approval in April 2025.

Investor Verification Checklist

• Verify the impact of the new Category I CPT codes on Q4 2025 and 2026 reimbursement rates and claim approval speeds.
• Monitor the timeline and terms of the new ATM offering registration statement to assess future equity dilution risks.
• Review the specific milestones required to maintain compliance with the Innovatus Loan Agreement covenants.
• Track the growth rate of active implanting centers and revenue per center to validate the sustainability of the 10% revenue growth trend.
• Assess the company's cash burn rate relative to the $85.1M cash balance to confirm the "two-year runway" assertion.